Close Menu

NEW YORK — Lucira Health, a developer of an instrument-free, low-cost molecular diagnostics platform for infectious disease testing, filed for a $115 million initial public offering with the US Securities and Exchange Commission last week.

In the filing, the Emeryville, California-based company said it intends to float an undisclosed number of shares on the Nasdaq at a yet-to-be-determined price under the ticker symbol LHDX. BofA Securities, LifeSci Capital, and William Blair are underwriting the IPO.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.